Dispelling Myths, Controversies,
& Urban Legends in EGFRm NSCLC
Promoting Evidence-Based Communication between Clinicians, Researchers, and Patient Advocates
The buttons above will connect you to our live zoom meeting (left) and allow you to download a PDF file of meeting resources. Use the button below to register for the meeting!
Invite your oncology team members to this free virtual event!
This live webinar is accredited for physicians, nurses, pharmacists, and physician assistants. Click the social links below to share!
Welcome & Introductions
7:00 PM – 7:10 PM
7:10 PM – 8:40 PM
Myth 1: There’s no need to wait for biomarker testing on new patients anymore with all the new immunotherapies out there.
Myth 2: I’ve heard it’s best to keep osimertinib as 2nd line therapy and start with a 1st/2nd generation EGFR TKI.
Myth 3: Liquid biopsies have replaced tissue biopsies to find biomarkers at the time of resistance.
Myth 4: Whole brain radiation for brain mets is the best option.
Myth 5: Once osimertinib treatment stops working, I have no other options.
Myth 6: Clinical trials are for people in the city or at big cancer centers.
8:40 PM – 9:00 PM